Generic Drugmakers Struggle Despite Us Push For Copycats | Latest News RSS feed

Generic Drugmakers Struggle Despite Us Push For Copycats - Latest News


Generic Drugmakers Struggle Despite U.S. Push for Copycats

Generic drugmakers are being crushed ... Just four of the 12 approved biologic copycat drugs are actually being sold, according to the generic-drug industry group the Association for Affordable Medici... read more

Generic drugmakers struggle to stay afloat

Many drugmakers have decried ... Just four of the 12 approved biologic copycat drugs are actually being sold, according to the generic-drug industry group the Association for Affordable Medicines, des... read more

Amgen Wins Reprieve on Its 2nd-Best-Selling Drug

That may mean it's only a matter of time before generic drug companies, including Mylan (NASDAQ: MYL), win FDA approval of biosimilar copycats. Unfortunately ... to $196 million. Amgen's struggle to m... read more

Looking for another news?


Generic drugs' troubled source

As U.S. regulators push hundreds of new generic drugs to market in an effort to drive down prices, the industry is facing a continuing problem in India, where many copycat medicines ... sending produc... read more


Drug companies rake in billions off ‘snort-proof’ opioids

But it’s also a multibillion-dollar sales opportunity, offering drugmakers the potential to wipe out lower-cost generic competitors and lock ... will give drugmakers momentum to successfully push for ... read more

Switzerland takes on its top drugmakers in price row

ZURICH, Sept 16 (Reuters) - Switzerland, home to the world’s two biggest drugmakers ... copycat drugs. Both Roche and Novartis remain sanguine that healthcare authorities and insurance companies will ... read more

Amgen Wins Reprieve on Its 2nd-Best-Selling Drug

That may mean it's only a matter of time before generic drug companies, including Mylan (NASDAQ: MYL), win FDA approval of biosimilar copycats ... to the tune of about $12 million per day. Despite Myl... read more

Switzerland takes on its top drugmakers in price row

* Pressure on drugmakers everywhere to cut prices * European countries, as growth slows, try to cut costs * But Switzerland's big two are important to economy, jobs * Roche, Novartis say low prices hu... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us